PRA Completes 20th First in Human Biologics Trial
PRA announced it has completed its 20th first in human trial with biologics.
PRA announced it has completed its 20th first in human trial with biologics. The milestone is the culmination of 600 subjects enrolled in over eight years of first in human biologics trials, including directly into patient experience. Biologics represent an important class of agents with an increasing share in modern medicine, as a response to improved understanding of molecular and genetic bases of disease.
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
